28 Jun Novo Nordisk
Salka E Rasmussen, Ph.D., Vice President, Head of Cell Therapy Inovation, Partnerships and Early Portfolio, Cell Therapy R&D
April 13 | 11:45am | BioCentriq Ballroom
Bagsværd, Denmark
(NOVO-B.CO)
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. For almost 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems. At Novo Nordisk, we are working to drive change to defeat diabetes and other serious chronic diseases. Our commitment to the research and development of cell therapies has the potential to realize that ambition over time, with our portfolio of emerging cell therapy programs. We are accelerating the research and development processes through global partnerships with world-leading experts and biotech companies, allowing us to deliver transformative cell therapies faster. Our organization spans the entire value chain from R&D to commercialization. This provides us with unique capabilities to research new cell therapies, accelerate clinical development, and manufacture within our own GMP facilities to ensure control over quality.
